1109 related articles for article (PubMed ID: 18484560)
1. A pilot study to examine the feasibility of insulin glargine in subjects with impaired fasting glucose, impaired glucose tolerance or new-onset type 2 diabetes.
Marbury TC; Schwartz S; Rosenberg MA; Jariwala N; Becker RH; Johnston PS
Exp Clin Endocrinol Diabetes; 2008 May; 116(5):282-8. PubMed ID: 18484560
[TBL] [Abstract][Full Text] [Related]
2. Dosing of insulin glargine in the treatment of type 2 diabetes.
Barnett A
Clin Ther; 2007 Jun; 29(6):987-99. PubMed ID: 17692716
[TBL] [Abstract][Full Text] [Related]
3. Insulin glargine in combination with nateglinide in people with Type 2 diabetes: a randomized placebo-controlled trial.
Dashora UK; Sibal L; Ashwell SG; Home PD
Diabet Med; 2007 Apr; 24(4):344-9. PubMed ID: 17298589
[TBL] [Abstract][Full Text] [Related]
4. Long-term beneficial effects of glipizide treatment on glucose tolerance in subjects with impaired glucose tolerance.
Eriksson JG; Lehtovirta M; Ehrnström B; Salmela S; Groop L
J Intern Med; 2006 Jun; 259(6):553-60. PubMed ID: 16704555
[TBL] [Abstract][Full Text] [Related]
5. Effects of 1-year treatment with metformin on metabolic and cardiovascular risk factors in non-diabetic upper-body obese subjects with mild glucose anomalies: a post-hoc analysis of the BIGPRO1 trial.
Fontbonne A; Diouf I; Baccara-Dinet M; Eschwege E; Charles MA
Diabetes Metab; 2009 Nov; 35(5):385-91. PubMed ID: 19665415
[TBL] [Abstract][Full Text] [Related]
6. Insulin glargine improves glycaemic control after coronary surgery in patients with diabetes or pre-diabetes.
Hagelberg A; Ivert T; Efendić S; Ohrvik J; Anderson RE
Scand Cardiovasc J; 2008 Feb; 42(1):71-6. PubMed ID: 18273733
[TBL] [Abstract][Full Text] [Related]
7. Clinical efficacy and tolerability of alpha-blocker doxazosin as add-on therapy in patients with hypertension and impaired glucose metabolism.
Pessina AC; Ciccariello L; Perrone F; Stoico V; Gussoni G; Scotti A; Muggeo M
Nutr Metab Cardiovasc Dis; 2006 Mar; 16(2):137-47. PubMed ID: 16487914
[TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of glargine compared with NPH insulin for the treatment of Type 2 diabetes: a meta-analysis of randomized controlled trials.
Bazzano LA; Lee LJ; Shi L; Reynolds K; Jackson JA; Fonseca V
Diabet Med; 2008 Aug; 25(8):924-32. PubMed ID: 18959605
[TBL] [Abstract][Full Text] [Related]
9. Comparison of glargine insulin versus rosiglitazone addition in poorly controlled type 2 diabetic patients on metformin plus sulfonylurea.
Triplitt C; Glass L; Miyazaki Y; Wajcberg E; Gastaldelli A; De Filippis E; Cersosimo E; DeFronzo RA
Diabetes Care; 2006 Nov; 29(11):2371-7. PubMed ID: 17065670
[TBL] [Abstract][Full Text] [Related]
10. Early insulin treatment to prevent cardiovascular disease in prediabetes and overt diabetes.
Roman G; Hancu N
Horm Metab Res; 2009 Feb; 41(2):116-22. PubMed ID: 19214921
[TBL] [Abstract][Full Text] [Related]
11. Comparison of pharmacokinetics and dynamics of the long-acting insulin analogs glargine and detemir at steady state in type 1 diabetes: a double-blind, randomized, crossover study.
Porcellati F; Rossetti P; Busciantella NR; Marzotti S; Lucidi P; Luzio S; Owens DR; Bolli GB; Fanelli CG
Diabetes Care; 2007 Oct; 30(10):2447-52. PubMed ID: 17623819
[TBL] [Abstract][Full Text] [Related]
12. Diabetes and impaired glucose tolerance prevalences in Turkish patients with impaired fasting glucose.
Tutuncuoğlu P; Saraç F; Saygili F; Ozgen AG; Yilmaz C; Tüzün M
Acta Diabetol; 2008 Sep; 45(3):151-6. PubMed ID: 18496644
[TBL] [Abstract][Full Text] [Related]
13. Albumin-bound basal insulin analogues (insulin detemir and NN344): comparable time-action profiles but less variability than insulin glargine in type 2 diabetes.
Klein O; Lynge J; Endahl L; Damholt B; Nosek L; Heise T
Diabetes Obes Metab; 2007 May; 9(3):290-9. PubMed ID: 17391154
[TBL] [Abstract][Full Text] [Related]
14. Reflecting on type 2 diabetes prevention: more questions than answers!
Rosenstock J
Diabetes Obes Metab; 2007 Sep; 9 Suppl 1():3-11. PubMed ID: 17877541
[TBL] [Abstract][Full Text] [Related]
15. Long-term glycaemic control with insulin glargine in Type 2 diabetes.
Kacerovsky-Bielesz G; Dressler A; Freunscht R
Diabetes Res Clin Pract; 2006 Feb; 71(2):184-91. PubMed ID: 16112241
[TBL] [Abstract][Full Text] [Related]
16. Insulin glargine (Lantus).
Owens DR; Griffiths S
Int J Clin Pract; 2002; 56(6):460-6. PubMed ID: 12166545
[TBL] [Abstract][Full Text] [Related]
17. Distribution of fasting plasma glucose and prevalence of impaired fasting glucose, impaired glucose tolerance and type 2 diabetes in the Mexican paediatric population.
Guerrero-Romero F; Violante R; Rodríguez-Morán M
Paediatr Perinat Epidemiol; 2009 Jul; 23(4):363-9. PubMed ID: 19523083
[TBL] [Abstract][Full Text] [Related]
18. Comparison of glycaemic control in patients with Type 2 diabetes on basal insulin and fixed combination oral antidiabetic treatment: results of a pilot study.
De Mattia G; Laurenti O; Moretti A
Acta Diabetol; 2009 Mar; 46(1):67-73. PubMed ID: 19030772
[TBL] [Abstract][Full Text] [Related]
19. Secondary diabetes associated with principal endocrinopathies: the impact of new treatment modalities.
Resmini E; Minuto F; Colao A; Ferone D
Acta Diabetol; 2009 Jun; 46(2):85-95. PubMed ID: 19322513
[TBL] [Abstract][Full Text] [Related]
20. The impact of insulin glargine on clinical and humanistic outcomes in patients uncontrolled on other insulin and oral agents: an office-based naturalistic study.
Fischer JS; McLaughlin T; Loza L; Beauchamp R; Schwartz S; Kipnes M
Curr Med Res Opin; 2004 Nov; 20(11):1703-10. PubMed ID: 15537471
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]